Abstract
USE OF GENOTYPE MTBDR ASSAY FOR MOLECULAR DETECTION OF RIFAMPIN AND ISONIAZID RESISTANCE IN MYCOBACTERIUM TUBERCULOSISCLINICAL STRAINS ISOLATED IN SUDAN

Ahmed Musa Abdallah*, Mohammed Ahmed Mohammed and Najwa Juda Adam

ABSTRACT

Introduction: The most effective first line drug against Mycobacterium tuberculosis are rifampicin and isoniazid, mutations in several gene determinant resistance Mycobacterium tuberculosis to isoniazid and most common gene target is katG and resistance rifampicin due to mutation in rpoB. The aim to assess to mutation in the gene region related to rifampicin and isoniazid. Methodology: A total of 200 smear positive samples were subjected to line probe assay using genotype MTB DR plus assay (HainLifescience Germany). Result: Out of 220 sputum samples, The smear positive were 200(90%) and smear negative were 20(10%), positive smears were subjected to MTBDR plus assay, Valid MTBDR plus assay results were obtained for 156 of 200 (78 %) . Of the 156, 80 (51.3%) tests were found to be resistant and 68(85%) of 80 were resistant to both RIF and INH, 76( 95 %) of 80 were resistant to RIF only, 78(97.5%) of 80 was isoniazid resistant were resistant to INH only. Conclusion:The high percentage of mutations in the rpoB and katG genes highlights their importance, and should be further investigated in order to gain a more comprehensive of the geographical distribution of resistant strains, as well as of the mechanisms underlying them.

Keywords: Mycobacterium Tuberculosis, Rifampicin, Mutations, Isoniazid, line Probe Assay, Sudan.


[Full Text Article]   [Download Certificate]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation

  • EJBPS: MAY ISSUE PUBLISHED

    MAY 2024 Issue has been successfully launched on 1 MAY 2024.

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT